Cannabis Workplace Impairment: Testing, Policies, and Legal Rights

Executive Summary

Cannabis workplace impairment has emerged as one of the most contentious legal and safety issues in American employment law, with no scientifically validated roadside or workplace test capable of measuring real-time intoxication. As of May 2026, 38 states have legalized cannabis in some form, yet employers face a patchwork of conflicting state laws, federal prohibition under the Controlled Substances Act (21 U.S.C. § 812), and evolving case law that offers little clarity on when and how they can discipline employees for cannabis use. Unlike alcohol, where a 0.08% blood alcohol concentration provides a clear legal standard, THC can remain detectable in blood and urine for weeks after use, long after psychoactive effects have subsided. This fundamental scientific limitation has created a collision between employee privacy rights, workplace safety obligations, and the operational realities of safety-sensitive industries. Recent data from the National Safety Council indicates that workplace drug testing positive rates for THC reached 4.2% in 2025, the highest level in two decades, while employers in states like California, New York, and New Jersey navigate new laws that restrict pre-employment testing and protect off-duty use. The stakes are measured in billions: workers' compensation claims, liability exposure, productivity losses, and the constitutional rights of medical cannabis patients who face termination despite never being impaired at work.

Why This Matters

The cannabis workplace impairment debate affects 164 million American workers, thousands of employers navigating conflicting legal obligations, and patients who risk losing their livelihoods for legal medicine. For employers, particularly in safety-sensitive sectors like transportation, construction, and healthcare, the absence of a reliable impairment test creates impossible choices. Federal contractors must maintain drug-free workplace policies under the Drug-Free Workplace Act of 1988, yet operate in states where cannabis is legal and employee protections are expanding. The U.S. Department of Transportation reported 55,582 positive cannabis tests among safety-sensitive transportation workers in 2025, but cannot distinguish between a driver who consumed cannabis 30 minutes before a shift and one who used it three weeks prior. For employees, the consequences are severe and often arbitrary. Medical cannabis patients with valid state authorizations have been terminated and denied unemployment benefits, with courts in multiple jurisdictions upholding employer rights to maintain zero-tolerance policies. A 2024 analysis by the National Organization for the Reform of Marijuana Laws found that medical cannabis patients lost employment discrimination cases in 78% of state court decisions, despite possessing legal prescriptions for conditions ranging from chronic pain to PTSD. The financial implications are substantial. The National Council on Compensation Insurance estimated that cannabis-related workers' compensation claims cost employers $1.3 billion in 2024, though causation remains disputed in most cases. Employers face potential liability under OSHA's General Duty Clause (29 U.S.C. § 654) to maintain safe workplaces, yet risk discrimination lawsuits when they discipline employees based on tests that cannot prove impairment. State legislatures are responding with divergent approaches. New York's Marijuana Regulation and Taxation Act prohibits employment discrimination based on off-duty cannabis use, while Montana's medical cannabis law explicitly allows employers to maintain zero-tolerance policies. This regulatory fragmentation forces multi-state employers to maintain different policies across their operations, creating compliance costs and inconsistent treatment of similarly situated employees.

Background and History: From Zero Tolerance to Legal Chaos

The modern workplace drug testing regime emerged from President Reagan's 1986 Executive Order 12564, which mandated drug-free federal workplaces and established the framework that private employers would adopt for decades.

The Reagan Era and the Birth of Workplace Testing (1986-1996)

Executive Order 12564, signed September 15, 1986, required federal agencies to establish drug testing programs for employees in sensitive positions. The order came amid the "War on Drugs" and growing concern about substance abuse in American workplaces. Congress reinforced this approach with the Drug-Free Workplace Act of 1988 (41 U.S.C. § 8101 et seq.), requiring federal contractors and grantees to certify they would maintain drug-free workplaces. The Department of Transportation implemented the most comprehensive testing regime through 49 C.F.R. Part 40, establishing mandatory random testing for safety-sensitive transportation workers. The DOT's drug testing program, which began in 1991, initially tested approximately 4 million covered employees annually, setting the standard that private employers would emulate across industries. During this period, courts consistently upheld employer rights to test and terminate for any drug use. The U.S. Supreme Court's decisions in Skinner v. Railway Labor Executives' Association (1989) and National Treasury Employees Union v. Von Raab (1989) established that drug testing of employees in safety-sensitive positions did not violate Fourth Amendment protections against unreasonable searches, even without individualized suspicion.

Medical Cannabis Collides with Zero Tolerance (1996-2012)

California's Proposition 215, passed in November 1996, created the first legal medical cannabis program in the United States, immediately generating conflict with established workplace policies. The California Supreme Court's 2008 decision in Ross v. RagingWire Telecommunications held that the Compassionate Use Act did not require employers to accommodate medical cannabis use, establishing a precedent that would be followed in most states for the next decade. During this period, employers maintained near-absolute authority to enforce zero-tolerance policies. Courts in Oregon (Emerald Steel Fabricators v. Bureau of Labor and Industries, 2010), Montana (Johnson v. Columbia Falls Aluminum Co., 2009), and Michigan (Casias v. Wal-Mart Stores, 2010) consistently ruled that state medical cannabis laws did not create employment protections or require reasonable accommodation under disability discrimination statutes. The testing technology remained unchanged: urinalysis detecting THC-COOH metabolites that could indicate use days or weeks prior, with no correlation to actual impairment. Quest Diagnostics reported that positive workplace drug tests for cannabis increased from 2.5% in 2010 to 2.8% in 2012, even as medical programs expanded to 18 states.

The Colorado Amendment and Federal-State Conflict (2012-2018)

Colorado's Amendment 64 and Washington's Initiative 502, both passed in November 2012, legalized adult-use cannabis and intensified the workplace testing debate. Colorado explicitly stated in its constitutional amendment that employers could maintain drug-free workplace policies and discipline employees for cannabis use, even off-duty. The Colorado Supreme Court's 2015 decision in Coats v. Dish Network became a landmark case. Brandon Coats, a quadriplegic medical cannabis patient, was terminated after testing positive for THC despite never using cannabis at work or being impaired on duty. The court held that because cannabis remained illegal under federal law, Coats's use was not "lawful" under Colorado's lawful off-duty activities statute, even though it was legal under state law. Federal agencies maintained strict prohibition. The Department of Transportation issued guidance in 2009 and updated it in 2014 clarifying that state cannabis laws did not alter federal testing requirements for safety-sensitive positions. Medical review officers were instructed to report all positive THC tests as violations, regardless of state medical authorizations.

The Accommodation Era Begins (2018-2026)

The landscape began shifting in 2018 when Massachusetts and Oklahoma courts issued decisions requiring employers to engage in the reasonable accommodation process for medical cannabis patients. The Massachusetts Supreme Judicial Court's decision in Barbuto v. Advantage Sales and Marketing held that the state's disability discrimination law required employers to consider accommodating off-duty medical cannabis use, absent evidence of actual impairment. New Jersey's Cannabis Regulatory, Enforcement Assistance, and Marketplace Modernization Act, effective February 22, 2021, prohibited employment discrimination based on cannabis use and required employers to prove impairment through "observable signs." The law marked a fundamental shift from detection-based policies to impairment-based standards, though it provided little guidance on how employers should document impairment. New York followed with the Marijuana Regulation and Taxation Act in March 2021, prohibiting pre-employment testing for cannabis (with exceptions for safety-sensitive positions) and barring discrimination based on off-duty use. The New York law explicitly stated that employers could not test for cannabis unless they had "specific articulable symptoms" of impairment. By 2024, Connecticut, Montana, Nevada, and Rhode Island had enacted varying levels of employment protection for cannabis users. California's AB 2188, effective January 1, 2024, prohibited employers from discriminating based on off-duty cannabis use and banned testing for non-psychoactive cannabis metabolites, effectively requiring employers to use blood, saliva, or observed impairment rather than urinalysis. The federal government began limited movement in 2024 when the Department of Health and Human Services recommended rescheduling cannabis from Schedule I to Schedule III under the Controlled Substances Act. While this would not legalize cannabis or alter workplace testing requirements, it acknowledged cannabis's accepted medical use, potentially undermining the Coats reasoning that cannabis use could never be "lawful activity."

Key Players in the Workplace Impairment Debate

Federal Agencies: DOT, OSHA, and SAMHSA

The Department of Transportation maintains the most stringent testing regime, covering approximately 12.5 million safety-sensitive transportation workers in aviation, trucking, railroads, mass transit, pipelines, and maritime operations. DOT's drug testing program under 49 C.F.R. Part 40 requires pre-employment, random, post-accident, reasonable suspicion, and return-to-duty testing, with a 5-nanogram-per-milliliter cutoff for THC in urine. The Federal Motor Carrier Safety Administration has consistently stated that state cannabis laws do not alter federal requirements, and commercial driver's license holders cannot use cannabis even in legal states. The Occupational Safety and Health Administration enforces workplace safety under the General Duty Clause but has issued limited guidance on cannabis impairment. OSHA's 2016 memo clarified that drug testing programs should not be used to retaliate against workers who report injuries, but the agency has not established impairment standards or testing protocols for cannabis. The Substance Abuse and Mental Health Services Administration establishes testing standards for federal workplace programs through its mandatory guidelines. SAMHSA's guidelines, codified at 49 C.F.R. Part 40, specify testing procedures, cutoff concentrations, and medical review officer protocols that have become industry standards beyond federal employment.

State Legislatures: Protection vs. Employer Rights

State approaches fall into four categories. Prohibition states like Arizona (prior to 2020) and Maine (prior to 2021) explicitly stated that medical cannabis laws created no employment protections. Accommodation states like Massachusetts, Connecticut, and New Jersey require employers to consider accommodating off-duty medical use absent safety concerns. Anti-discrimination states like New York and California prohibit adverse employment actions based on off-duty use or positive tests for non-psychoactive metabolites. Silence states like Colorado and Washington include no employment protections in their cannabis laws, leaving the issue to courts and common law.

Employers and Industry Groups

The U.S. Chamber of Commerce has consistently advocated for employer rights to maintain drug-free workplaces, arguing that federal prohibition and safety obligations require continued testing authority. The National Safety Council published "Employer Guidance on Cannabis" in 2019, recommending that employers focus on impairment rather than detection, but acknowledging the lack of reliable impairment tests. Safety-sensitive industries face unique pressures. The American Trucking Associations reported that cannabis-positive test rates among truck drivers increased 24% between 2023 and 2025, raising concerns about highway safety even as the industry faces severe driver shortages. Construction industry groups have noted that workers' compensation insurers are increasing premiums or requiring enhanced drug testing programs in legal cannabis states.

Employee Advocates and Medical Cannabis Patients

The National Organization for the Reform of Marijuana Laws has litigated employment discrimination cases across multiple states, arguing that terminating medical patients for off-duty use violates disability discrimination laws and public policy. Americans for Safe Access has advocated for federal rescheduling and state-level employment protections, emphasizing that patients should not be forced to choose between effective medicine and employment. Labor unions have taken varied positions. The United Food and Commercial Workers, which represents cannabis industry workers, has advocated for employee protections and impairment-based testing. Building trades unions, concerned about construction site safety, have generally supported continued testing authority for employers in safety-sensitive positions.

Legal and Regulatory Framework

The legal framework for cannabis workplace impairment rests on the tension between federal prohibition under the Controlled Substances Act and expanding state legalization and employee protection laws. The Controlled Substances Act (21 U.S.C. § 812) classifies cannabis as a Schedule I controlled substance, defined as having no accepted medical use and high potential for abuse. This federal prohibition provides the foundation for employer zero-tolerance policies and has been cited by courts as justification for denying employment protections to cannabis users, even in legal states. The Americans with Disabilities Act (42 U.S.C. § 12101 et seq.) explicitly excludes current illegal drug users from protection, and courts have consistently held that this exclusion applies to cannabis users because of federal prohibition, regardless of state law. However, some state disability discrimination laws do not contain similar exclusions, creating the basis for accommodation requirements in states like Massachusetts and Connecticut. State cannabis laws vary dramatically in their employment provisions. California Health and Safety Code § 11362.45 originally stated that the medical cannabis law did not require employers to accommodate use, but AB 2188 amended the law in 2024 to prohibit discrimination based on off-duty use or tests for non-psychoactive metabolites. New York Cannabis Law § 201-d prohibits discrimination based on legal off-duty activities, which courts have interpreted to include cannabis use. New Jersey's Cannabis Regulatory Act at N.J.S.A. 24:6I-52 requires employers to treat cannabis like alcohol, prohibiting adverse actions unless the employer can demonstrate impairment through "physical, behavioral, or performance indicators." Workers' compensation statutes in multiple states include rebuttable presumptions that workplace injuries are not compensable if the employee tests positive for cannabis. Montana Code Annotated § 39-71-407 creates such a presumption, placing the burden on the injured worker to prove that cannabis use did not contribute to the injury. Colorado's workers' compensation statute contains a similar provision at C.R.S. § 8-42-112.5. The Drug-Free Workplace Act (41 U.S.C. § 8101 et seq.) requires federal contractors to maintain drug-free workplace policies but does not mandate drug testing. Contractors must prohibit controlled substance use, establish awareness programs, and take action against employees who violate drug policies. Federal contractors argue that state cannabis laws cannot override these federal requirements, creating a carve-out for safety-sensitive and federal contractor positions even in states with strong employee protections.

State-by-State Breakdown of Employment Protections

State	Legal Status	Employment Protections	Testing Restrictions	Key Statute/Case
California	Adult-use legal	Prohibits discrimination for off-duty use; cannot test for non-psychoactive metabolites	Urinalysis effectively banned for employment decisions (as of 2024)	AB 2188 (Gov. Code § 12954)
New York	Adult-use legal	Prohibits discrimination; no pre-employment testing except safety-sensitive	Requires "articulable symptoms" for testing	Cannabis Law § 201-d
New Jersey	Adult-use legal	Prohibits discrimination; requires proof of impairment	Must document "observable signs" of impairment	N.J.S.A. 24:6I-52
Connecticut	Adult-use legal	Requires reasonable accommodation for medical patients	Cannot test solely based on status as medical patient	Conn. Gen. Stat. § 21a-408p
Massachusetts	Adult-use legal	Requires reasonable accommodation for medical patients absent safety concerns	No specific restrictions	Barbuto v. Advantage Sales (2017)
Colorado	Adult-use legal	None; employers may enforce zero-tolerance policies	No restrictions	Coats v. Dish Network (2015)
Washington	Adult-use legal	None; cannabis use not protected off-duty activity	No restrictions	RCW 69.50 (silent on employment)
Nevada	Adult-use legal	Prohibits refusing to hire based on positive pre-employment test	Pre-employment testing restricted except safety-sensitive	NRS 613.333
Illinois	Adult-use legal	Limited; employers may enforce zero-tolerance for safety-sensitive positions	Cannot discriminate solely based on registered medical patient status	410 ILCS 705/10-50
Michigan	Adult-use legal	None for adult-use; limited for medical patients	No restrictions	Casias v. Wal-Mart (2010)
Arizona	Adult-use legal	Prohibits discrimination against medical patients unless impaired at work	Cannot discriminate based on positive test alone for medical patients	A.R.S. § 36-2813
Montana	Adult-use legal	Requires reasonable accommodation for medical patients	No specific restrictions	MCA 50-46-307 (as amended 2021)
Rhode Island	Adult-use legal	Prohibits discrimination against medical patients	Cannot refuse employment based solely on medical patient status	R.I. Gen. Laws § 21-28.6-7
Pennsylvania	Medical only	Prohibits discrimination against medical patients absent impairment	Cannot discriminate based solely on patient status	35 P.S. § 10231.2103
Ohio	Adult-use legal (as of 2024)	None; employers may refuse to hire or discharge for cannabis use	No restrictions	Ohio Rev. Code § 3780.13

Market and Business Implications

The cannabis workplace impairment issue creates billions in compliance costs, liability exposure, and operational complexity for American businesses while reshaping labor markets in legal states. Employers face a three-part cost structure. First, drug testing program costs average $42 per test for urinalysis and $75-125 for oral fluid testing, according to the Substance Abuse Program Administrators Association. Large employers conducting hundreds of thousands of tests annually spend millions on testing alone. Second, legal compliance costs have escalated as employers revise policies, train supervisors, and defend employment decisions across multiple state regimes. Third, liability exposure has increased as wrongful termination claims, disability discrimination lawsuits, and workers' compensation disputes proliferate. The insurance industry has responded with premium adjustments and policy exclusions. Workers' compensation carriers in California, Colorado, and Washington have implemented surcharges of 5-15% for employers in high-risk industries that do not maintain drug testing programs. General liability insurers have added cannabis-related exclusions to employment practices liability policies, forcing employers to purchase separate coverage or accept coverage gaps. Talent acquisition has become more challenging in tight labor markets. A 2025 Society for Human Resource Management survey found that 38% of employers in legal cannabis states had eliminated pre-employment cannabis testing for non-safety-sensitive positions, citing difficulty filling positions and state law restrictions. Technology companies, hospitality operators, and retailers have led this trend, while healthcare, transportation, and manufacturing have maintained testing requirements. Multi-state operators face the highest compliance burden. A company operating in California, Texas, and New York must maintain three different drug testing policies: California prohibits testing for non-psychoactive metabolites, Texas allows zero-tolerance policies, and New York restricts pre-employment testing and requires articulable impairment symptoms. Employment law firms report that multi-state policy development and training costs range from $50,000 to $500,000 depending on company size and geographic footprint. The cannabis industry itself faces unique challenges. Cannabis cultivation, processing, and retail facilities must comply with state regulations requiring background checks and, in some states, drug testing of employees handling cannabis products. The irony of cannabis workers being fired for using the products they sell has generated litigation and union organizing efforts. Capital markets have taken note. Publicly traded companies, particularly those in safety-sensitive industries, disclose cannabis-related risks in SEC filings. Major trucking companies have reported that driver shortages are exacerbated by high cannabis-positive test rates, with some carriers unable to fill 10-15% of available positions due to applicants failing drug screens.

What Experts Say About Impairment Testing and Policy

Toxicologists, occupational medicine physicians, and workplace safety researchers agree that current testing technology cannot reliably measure cannabis impairment, creating a scientific gap that policy has failed to address. Dr. Marilyn Huestis, a leading cannabis researcher formerly with the National Institute on Drug Abuse, has stated in published research that THC blood concentrations decline rapidly after use, but that no specific blood THC level correlates reliably with impairment across all users. According to her research published in Clinical Chemistry, occasional users may show impairment at 2-5 nanograms per milliliter of blood THC, while frequent users may show no impairment at 20-30 nanograms per milliliter due to tolerance. The National Safety Council's 2021 position statement on cannabis impairment concluded that employers should focus on observable signs of impairment rather than drug testing alone, but acknowledged that supervisor training and documentation requirements create significant implementation challenges. The organization recommended a multi-faceted approach including policy clarity, supervisor training, and fitness-for-duty evaluations. Dr. Igor Grant, director of the Center for Medicinal Cannabis Research at UC San Diego, has testified in multiple court cases that cannabis impairment typically resolves within 3-4 hours of use for most individuals, though residual effects may persist longer in some users. His research, funded by the State of California, found that driving simulator performance returned to baseline within 2.5 hours for most subjects after vaporizing cannabis, even though blood THC remained detectable. Occupational medicine specialists have noted the disconnect between legal standards and scientific evidence. Dr. Robert Pandina, director of the Rutgers Center of Alcohol Studies, stated in a 2024 interview with Occupational Health & Safety magazine that employers need better tools than urinalysis, which he described as "essentially useless for determining workplace impairment" because it detects metabolites that persist long after psychoactive effects end. Labor economists have documented the employment effects of cannabis legalization and workplace policies. Research published in the Journal of Policy Analysis and Management in 2023 found that states with employee protections for off-duty cannabis use saw no statistically significant increase in workplace injuries compared to states maintaining zero-tolerance policies, suggesting that fears of impaired workers causing accidents may be overstated. Legal scholars have criticized the patchwork of state laws and called for federal clarity. Professor Alex Kreit of Northern Kentucky University's Salmon P. Chase College of Law has argued that the Coats decision's reliance on federal illegality to deny state law protections creates an untenable situation where state legalization is effectively meaningless for workers. He has advocated for federal rescheduling or descheduling to resolve the conflict.

What's Next: Legal, Regulatory, and Technological Developments

The cannabis workplace impairment landscape will be shaped by three parallel developments: state legislative action, federal rescheduling proceedings, and emerging impairment detection technology. On the state legislative front, at least 12 states are considering employment protection bills in 2026 legislative sessions, according to the National Conference of State Legislatures. Florida, Minnesota, and Maryland are debating measures that would prohibit pre-employment testing and require impairment-based discipline. Employer groups are lobbying for carve-outs for safety-sensitive positions and preservation of workers' compensation defenses. The federal rescheduling process represents the most significant potential shift. The Drug Enforcement Administration's notice of proposed rulemaking to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act entered the public comment period in 2024, with a final rule expected in late 2026 or early 2027. If cannabis is rescheduled to Schedule III, it would remain a controlled substance, but the acknowledgment of accepted medical use could undermine court decisions like Coats that rely on federal illegality to deny employment protections. However, rescheduling would not automatically alter DOT testing requirements or create federal employment protections. Technology development offers potential solutions but faces validation challenges. Several companies have developed oral fluid tests, breathalyzers, and eye-tracking systems that claim to detect recent use or impairment. Hound Labs' cannabis breathalyzer, which received limited law enforcement deployment in 2024, detects THC in breath for approximately 2-3 hours after use. The device has a detection threshold of 500 picograms per liter of breath, but has not been validated in peer-reviewed studies for workplace use or adopted by federal agencies. SannTek Labs and Impairment Science have developed cognitive impairment tests that measure reaction time, decision-making, and coordination without detecting drug presence. These applications, used on tablets or smartphones, compare an individual's current performance to their baseline, potentially identifying impairment from any cause including cannabis, fatigue, or illness. However, no cognitive impairment test has been approved by DOT or adopted as a legal standard in any state, and questions remain about accuracy, legal admissibility, and privacy implications. The legal calendar includes several significant cases. The New Jersey Supreme Court is expected to rule in 2026 on what constitutes sufficient "observable signs" of impairment to justify discipline under the state's cannabis law. The Pennsylvania Commonwealth Court is considering whether the state's medical cannabis law requires accommodation for safety-sensitive positions. Federal appellate courts in the Second and Ninth Circuits have employment discrimination cases on their dockets that could clarify the interaction between state cannabis laws and federal disability statutes. Workers' compensation boards in multiple states are developing guidance on the rebuttable presumption issue. The Colorado Division of Workers' Compensation convened a stakeholder group in 2025 to recommend standards for rebutting the presumption that injuries are not compensable when workers test positive for THC. The group is considering factors including time between use and injury, job duties, accident circumstances, and witness statements. Industry groups are developing best practices in the absence of legal clarity. The American Society of Safety Professionals published updated guidance in 2025 recommending that employers in legal states adopt impairment-based policies, train supervisors on observable signs of impairment, and document specific behaviors rather than relying solely on drug test results. The guidance includes checklists for supervisors documenting suspected impairment, covering factors such as slurred speech, coordination problems, altered reaction time, and unusual behavior.

Further Reading and Primary Sources

• Drug-Free Workplace Act of 1988, 41 U.S.C. § 8101 et seq. - https://www.govinfo.gov/content/pkg/USCODE-2011-title41/pdf/USCODE-2011-title41-chap81.pdf
• Department of Transportation Drug and Alcohol Testing Regulations, 49 C.F.R. Part 40 - https://www.ecfr.gov/current/title-49/subtitle-A/part-40
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/pdf/USCODE-2021-title21-chap13-subchapI-partB-sec812.pdf
• Coats v. Dish Network, 350 P.3d 849 (Colo. 2015) - https://www.courts.state.co.us/Courts/Supreme_Court/Opinion/2015/13SC394.pdf
• Barbuto v. Advantage Sales and Marketing, 477 Mass. 456 (2017) - https://www.mass.gov/files/documents/2017/07/28/sjc-12226.pdf
• California Assembly Bill 2188 (2024), amending Gov. Code § 12954 - https://leginfo.legislature.ca.gov/faces/billNavClient.xhtml?bill_id=202120220AB2188
• New York Cannabis Law § 201-d - https://www.nysenate.gov/legislation/laws/LAB/201-D
• New Jersey Cannabis Regulatory Act, N.J.S.A. 24:6I-52 - https://www.njleg.state.nj.us/bill-search/2020/A21
• National Safety Council, "Employer Guidance on Cannabis" (2019) - https://www.nsc.org/workplace/safety-topics/drugs-at-work
• Quest Diagnostics Drug Testing Index - https://www.questdiagnostics.com/business-solutions/employer-solutions/drug-testing/drug-testing-index
• SAMHSA Mandatory Guidelines for Federal Workplace Drug Testing Programs - https://www.samhsa.gov/workplace/drug-testing
• Americans with Disabilities Act, 42 U.S.C. § 12101 et seq. - https://www.ada.gov/law-and-regs/ada/
• National Organization for the Reform of Marijuana Laws, Employment Rights - https://norml.org/marijuana/fact-sheets/item/marijuana-and-employment
• Society for Human Resource Management, "Managing Marijuana in the Workplace" - https://www.shrm.org/topics-tools/news/managing-marijuana-workplace
• Occupational Safety and Health Administration General Duty Clause, 29 U.S.C. § 654 - https://www.osha.gov/laws-regs/oshact/section5-duties